RSS   Newsletter   Contact   Advertise with us
Post Online Media
Pharma industry   Vertex have agreed to pay $160m in cash

Concert Pharma sells drug to Vertex, shares skyrocket 81%

Concert PharmaceuticalsConcert Pharmaceuticals' share price shot up more than 80% on Monday after the company announced a deal to sell its cystic fibrosis drug CTP-656 to Vertex Pharmaceuticals for $250m.

Concert also released its fiscal results for the final quarter of 2016, showing a loss of $50.7m for the period.

Article continues below

READ MORE Texas company Vertex buys Heartland Petroleum

CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) and is currently in Phase II of trials in order to become available in the US, UK, Germany and France.

Vertex have agreed to pay $160m in cash for the drug, as well as $90m based on future assurances of it being approved.

"With Vertex's clinical and commercial expertise in CF, this agreement provides the optimal pathway to rapidly advance the development of CTP-656 for the benefit of cystic fibrosis patients," said Roger Tung, Chief Executive Officer of Concert Pharmaceuticals.

"The financial strength provided to Concert by this agreement will allow us to advance CTP-543 into pivotal testing and broaden our proprietary development pipeline."

Concert's total revenue for Q4 was down to $174,000, compared with $66.7m in the corresponding quarter of 2015.




What to read next





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy